CONSORTIUM ON BETA CELL DEATH AND SURVIVAL

CBDS is using human pancreatic tissues to discover mechanisms of cellular stress or dysfunction that may contribute to the development of autoimmunity in at-risk individuals, to identify specific biomarkers of the asymptomatic phase of T1D, and to develop innovative strategies to stop beta cell destruction early in the disease process.

Projects

CBDS | 8.31.20

Development of an Early Diagnostic Biomarker and Novel Treatment Strategy for T1D Read more →

CBDS | 8.31.20

Discovery and Investigation of Noninvasive Diagnostic Potential of Circulating Pancreatic Islet Beta Cell Exosomes as Biomarkers of Beta Cell Injury Read more →

CBDS | 8.31.20

Drivers and Consequences of Beta Cell DNA Damage in Type 1 Diabetes Read more →

CBDS | 8.31.20

Development of an Early Diagnostic Biomarker and Novel Treatment Strategy for T1D Read more →

CBDS | 8.31.20

Discovery and Investigation of Noninvasive Diagnostic Potential of Circulating Pancreatic Islet Beta Cell Exosomes as Biomarkers of Beta Cell Injury Read more →

CBDS | 8.31.20

Drivers and Consequences of Beta Cell DNA Damage in Type 1 Diabetes Read more →

CBDS | 8.31.20

Development of an Early Diagnostic Biomarker and Novel Treatment Strategy for T1D Read more →

CBDS | 8.31.20

Discovery and Investigation of Noninvasive Diagnostic Potential of Circulating Pancreatic Islet Beta Cell Exosomes as Biomarkers of Beta Cell Injury Read more →

CBDS | 8.31.20

Drivers and Consequences of Beta Cell DNA Damage in Type 1 Diabetes Read more →

CDBS Members

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

John Doe
Descriptions goes here.

Other Consortias

CHIB

CMAI

CTAR

HPAC

Subscribe to our Newsletter